Thyrocare Technologies Ltd · NSE:THYROCARE
Thyrocare Technologies — Q4 FY22 Earnings Presentation
22 slides from Thyrocare Technologies's earnings presentation, Apr 30, 2022
Slide 1: Thyrocare cover letter to stock exchanges
Thyrocare’ The Trust. The Truth. April 30, 2022 To, National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 Dear Sirs, Sub: Presentation on Audited Financial Results for the quarter
Slide 2: Thyrocare Technologies Limited Quarterly Presentation – March 2022
Thyrocare Technologies Limited Quarterly Presentation – March 2022 0
Slide 3: Agenda
Agenda 1 Setting the baseline - drivers for FY22 2 Going forward - key strategic drivers and progress 3 Summary results & Q&A 1
Slide 4: Revenue breakdown for FY22
Revenue breakdown for FY22 Total Pathology Revenue (in crore) Q1-22 Q2-22 Q3-22 Q4-22 FY22 159.26 168.74 110.20 123.33 561.53 Diagnostic Services (in crore) Sale of Goods (in crore) Q1-22 Q2-22 Q3-22 Q4-22 FY22 Q1-22 Q2-22 Q3-22 Q4-22 FY22 152.84 164.94 106.00 117.58 541.36 6.42 3.80 4.20 5.75 20.17
Slide 5: Resetting the base: A de-averaged view of COVID vs. NON COVID business
Resetting the base: A de-averaged view of the COVID vs. NON COVID business … Total Pathology P&L Total Pathology COVID P&L Total Pathology NON COVID P&L P&L FY21 FY22 Gr(%) P&L FY21 FY22 Gr (%) P&L FY21 FY22 Gr (%) Revenue 474.27 561.53 18% Revenue 151.39 171.01 13% Revenue 322.88 390.52 21% GM 313.
Slide 6: Accounting for COVID recovery in Q1 between FY21 and FY22
… and accounting for COVID recovery in Q1 between FY21 and FY22 Total Pathology P&L Total Pathology COVID P&L Total Pathology NON COVID P&L P&L Q2-Q4 21 Q2-Q4 22 Gr(%) P&L Q2-Q4 21 Q2-Q4 22 Gr(%) P&L Q2-Q4 21 Q2-Q4 22 Gr(%) Revenue 419.87 402.27 -4% Revenue 127.65 102.58 -20% Revenue 292.22 299.69 3
Slide 7: Our NON COVID business has recovered significantly vs. pre-COVID levels
However, as we look at the year, our NON COVID business has recovered significantly vs. pre-COVID levels In Q4 FY22, we have recovered to pre- Continued focus on NON COVID business to drive the recovery of the COVID in B2B, growth in B2C business Diagnostic Services Revenue (Rs Cr) Diagnostic Servic
Slide 8: Driving volumes in NON COVID business, March exit at all time high
Our focus has been on driving volumes in the NON COVID business, March exit at an all time high in NON COVID, lowest levels in COVID volumes Diagnostic Services Revenue (Rs Cr) Diagnostic Services Workload (Lakhs) NON COVID 50 30 COVID 41 All time high 40 21 32 31 32 31 32 32 29 31 20 30 28 28 27 30
Slide 9: B2B and B2C verticals well on their way to recovery
Our B2B and B2C verticals are well on their way to recovery – particularly in last 4-5 months, both in revenue and volume terms NON COVID Diagnostics Services Revenue (Rs Cr) NON COVID Diagnostics Services Workload (Lakhs) 40 20 18.1 30.3 30 12.4 12.4 22.7 23.1 24.3 23.2 23.8 22.9 22.6 23.3 11.7 11.
Slide 10: AAROGYAM and NON-AAROGYAM recovery; Top 100 clients driving growth
While our AAROGYAM business has picked up, our NON-AAROGYAM business has recovered significantly as well – additionally our Top 100 clients have driven a significant growth NON COVID Revenue (Rs Cr) AAROGYAM NON-AAROGYAM NON COVID Revenue (Rs Cr) Top 100 clients 45 9 41 8 40 8 35 32 31 32 7 31 31 32
Slide 11: Agenda
Agenda 1 Setting the baseline - drivers for FY22 2 Going forward - key strategic drivers and progress 3 Summary results & Q&A 9
Slide 12: API + Thyrocare stronger together – an 8 point agenda
API + Thyrocare stronger together – an 8 point agenda + 1 Serve Pharmeasy Online customer base of 2.1 5 Continue to improve our value proposition to our M quarterly transacting users franchisee network, expand aggressively 2 Partner with Retailio & MARG retailer network 6 Focus on our Health package
Slide 13: The combination of Pharmeasy and Thyrocare is uniquely advantaged in diagnostics
The combination of Pharmeasy and Thyrocare is uniquely advantaged in the diagnostics space Benchmarking Pharmeasy + Thyrocare Digital diagnostics Standalone diagnostic Healthcare platforms player Product & tech depth Tech team spread Focused on single Digital strength is Spread across across 4 large
Slide 14: Continued efforts to maximize Thyrocare as a B2B brand in diagnostics
Continued efforts maximize Thyrocare as a B2B brand in diagnostics Addressing Quality Doctor Working on Network Menu churn perception Engagement TAT expansion expansion All time high of Hosted 67% of samples Pan India Extensive test 3 Labs accredited 21 Lakh roundtable on reach our lab presence menu
Slide 15: Full power of the API network being leveraged to drive diagnostics
Full power of the API network being leveraged to drive diagnostics Collection Cross-sell Consultation Hospitals Pharmacies centers Targeting to reach 7% 6,000 Super-retailers cross-sell (Pharmeasy Targeting to have 1,000 Leveraging our Hospital 4200 prescribing doctors selling Diagnostics by users b
Slide 16: Our focus areas for the next growth horizons
Our focus areas for the next growth horizons 400 Cr Next 3 years FY25 Next3 years FY28 NON COVID Horizon 1 Horizon 2 in FY22 Current Focus Strategic Platforms Strategic Platforms • Addressing churn • Target 15% of Pharmeasy users on the • Continue to expand cross- • Quality perception platform for c
Slide 17: Agenda
Agenda 1 Setting the baseline - drivers for FY22 2 Going forward - key strategic drivers and progress 3 Summary results & Q&A 15
Slide 18: Key Highlights - Pathology
Key Highlights - Pathology Revenue YoY Revenue from operations of Rs. 562 Crore, grown by 18% YOY. Revenue for the final quarter of the year of Rs. 123 Rs. 562 18% ↑ Crore, grown by 12% in sequential quarters mainly with revival of the base non covid business. Revenue from COVID Crore business was f
Slide 19: Income Statement - Pathology
Income Statement - Pathology Pathology business grew by 12% in sequential quarter and yearly by 18%. Growth in the current quarter was mainly on account of revival of B2B non COVID business. Revenue from operations – primarily comprised of Revenue from diagnostic services Rs. 117 Income Statement cr
Slide 20: Income Statement - Radiology
Income Statement - Radiology Radiology business accounted for about 5% of reported consolidated revenue of Thyrocare Group revived significantly after complete shut down for couple of months in covid and thereafter out of the impact of lockdowns, posting 34% YOY growth in the current year. Income St
Slide 21: Income Statement - Consolidated
Income Statement - Consolidated Consolidated annual revenue of the group grew by 19% YOY, with positive signs of revival in non covid business. COVID business significantly eroded in last two quarters and radiology business growing at pre COVID level. Revenue from operations – primarily comprised of
Slide 22: Thank You
Thank You Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development,
Thyrocare Technologies — Q4 FY22 Earnings Presentation on 6ix